Standard dosage and usage of trametinib (Megenin) and patient-specific dose adjustment

Trametinib is a MEK inhibitor that is often combined with dabrafenib to treat BRAF V600 mutant melanoma and some non-small cell lung cancer. The standard recommended dose is usually 2mg taken orally once a day and does not need to be taken with food. However, it is recommended to take the drug at a fixed time every day to maintain stable blood concentration. This medicine should be swallowed whole and should not be broken or chewed to avoid affecting the efficacy of the medicine. Patients should regularly review blood routine, liver, kidney and heart function during medication to ensure medication safety.

Although there is a clear standard dose, in actual clinical practice, the dosage of trametinib needs to be individually adjusted according to the patient's physical condition. Common adverse reactions include rash, diarrhea, abnormal cardiac function, retinopathy, etc. If moderate to severe side effects occur, doctors may recommend temporarily discontinuing the drug or reducing the dose. The common dose after reduction is 1.5 mg per day. If it is still intolerable, it may be further reduced to 1 mg until a dose range that is tolerated and effective by the patient is found.

Dose adjustments are usually based on the severity of adverse reactions (e.g.CTCAEcriteria), as well as the patient's underlying disease and tolerability. For example, if a patient experiences persistent or severe skin toxicity, the drug can be suspended first and resumed at a lower dose after the symptoms are relieved; if there is a decrease in cardiac ejection fraction or serious ophthalmic adverse reactions, the drug may need to be permanently discontinued. In addition, when other drugs are used concomitantly, the dose of trametinib may need to be adjusted due to drug interactions.

To ensure the therapeutic effect and safety, patients should follow the doctor's guidance while taking trametinib and are not allowed to increase or decrease the dose or stop the drug on their own. During the treatment process, regular follow-up should be maintained, cardiac color ultrasound and eye examinations should be performed regularly, and adverse reactions should be reported in a timely manner so that doctors can make dose adjustments or auxiliary treatments. Generally speaking, the standard dose of trametinib is 2mg/day, but the actual clinical medication regimen needs to be flexibly adjusted according to individual differences to ensure the efficacy while minimizing toxic and side effects and improving the patient's quality of life.

Reference materials:https://www.drugs.com/